BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q1 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $84,000 | -32.3% | 10,800 | -55.6% | 0.00% | -57.1% |
| Q1 2021 | $124,000 | +100.0% | 24,300 | +125.0% | 0.01% | +75.0% |
| Q1 2020 | $62,000 | -92.9% | 10,800 | -50.3% | 0.00% | -91.7% |
| Q4 2019 | $879,000 | +7225.0% | 21,730 | +94.0% | 0.05% | +4700.0% |
| Q4 2016 | $12,000 | -99.9% | 11,200 | -95.4% | 0.00% | -99.8% |
| Q3 2016 | $11,594,000 | +11.0% | 243,561 | +5.4% | 0.41% | -33.1% |
| Q2 2016 | $10,448,000 | +172.3% | 231,038 | -71.6% | 0.61% | +118.2% |
| Q1 2016 | $3,837,000 | +328.2% | 813,094 | +90.2% | 0.28% | +551.2% |
| Q4 2015 | $896,000 | +554.0% | 427,400 | +547.6% | 0.04% | +514.3% |
| Q3 2015 | $137,000 | -90.7% | 66,000 | +48.1% | 0.01% | -92.1% |
| Q2 2015 | $1,470,000 | +58.7% | 44,574 | +229.8% | 0.09% | +41.3% |
| Q1 2015 | $926,000 | -17.1% | 13,516 | -11.4% | 0.06% | +53.7% |
| Q4 2014 | $1,117,000 | -40.5% | 15,247 | -41.7% | 0.04% | -44.6% |
| Q3 2014 | $1,878,000 | -33.2% | 26,163 | -32.7% | 0.07% | -28.8% |
| Q2 2014 | $2,811,000 | +1122.2% | 38,877 | -78.6% | 0.10% | +1385.7% |
| Q4 2013 | $230,000 | -60.5% | 181,700 | -45.4% | 0.01% | -65.0% |
| Q2 2013 | $583,000 | – | 332,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |